Condition: Cardiomyopathy, Hypertrophic · Sponsor: Bristol-Myers Squibb
The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Local Institution - 0082 | Birmingham, Alabama, United States | — |
| Local Institution - 0458 | Phoenix, Arizona, United States | — |
| Local Institution - 0409 | La Jolla, California, United States | — |
| Local Institution - 0010 | Los Angeles, California, United States | — |
| Local Institution - 0406 | San Francisco, California, United States | — |
| Local Institution - 0079 | Stanford, California, United States | — |
| Local Institution - 0468 | Gainesville, Florida, United States | — |
| Local Institution - 0281 | Tampa, Florida, United States | — |
| Local Institution - 0092 | Atlanta, Georgia, United States | — |
| Local Institution - 0424 | Indianapolis, Indiana, United States | — |
| Local Institution - 0070 | Iowa City, Iowa, United States | — |
| Local Institution - 0410 | Kansas City, Kansas, United States | — |
+ 212 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05582395